ALS gene hunt: vitamin d clues under microscope
NCT ID NCT02893605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at genetic differences in vitamin D processing and action in 400 people with ALS and 400 healthy controls. Researchers analyzed DNA samples to find variations in eight specific genes. The goal was to better understand the biology of ALS, not to test a new drug or treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help researchers understand how vitamin D-related genes might influence ALS, potentially pointing toward new avenues for future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks at genetic differences and does not test any therapy, so it cannot directly lead to a cure or symptom relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
800 people
The number who actually took part.
- Start date
-
Mar 2014
- Finished
-
Dec 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
A national biological (France) collection has been in existence since 1996 and serves as a source for patient and control samples. Patients have a sporadic form of Amyotrophic Lateral Sclerosis and controls are their spouses/partners.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The primary inclusion criterium is the same for that of the parent biological collection, i.e. the patients fulfill requirements for probable or definite Amyotrophic Lateral Sclerosis as defined by revised international criteria (Brooks et al 2000). * Additionally, included patients were followed-up by doctors at the University Hospital of Montpellier, thus enabling verification of Amyotrophic Lateral Sclerosis criteria over time. Exclusion Criteria: * The patient has a familial form of Amyotrophic Lateral Sclerosis (autosomic dominant or recessive types) with or without a mutation of one of the 3 genes known to be responsible for familial forms (SOD1, TARDBP, FUS). See Bender (1998).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a NAD-Boosting supplement slow ALS? extension trial tests nicotinamide riboside and pterostilbene
- Breathing support in ALS: what it means for patients and families
- Virtual reality and robots put to the test in neuromuscular rehab
- Breathing device tested to slow lung decline in ALS
- Can hospital codes reliably track home ventilation in ALS?